Literature DB >> 2464737

Suppression of HBsAg production in PLC/PRF/5 human hepatoma cell line by interferons.

Y Yamashita1, K Koike, M Takaoki, S Matsuda.   

Abstract

Recombinant human interferon alpha 2a as well as natural human interferons alpha and beta significantly suppressed the production of hepatitis B surface antigen by PLC/PRF/5 cells (which have been established from a human primary hepatocellular carcinoma and proven to carry the hepatitis B virus DNA) and inhibited proliferation of these cells in vitro. However, the production of alpha-fetoprotein by PLC/PRF/5 cells was less significantly affected by any of the interferons. These results suggest that these interferons not only suppress cellular proliferation but also selectively inhibit the action of the HBV gene which is persistently present in these cells.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2464737     DOI： 10.1111/j.1348-0421.1988.tb01476.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN： 0385-5600            Impact factor:   1.955


  7 in total

1.  Prevention of hepatocellular carcinoma.

Authors:  Michael C Kew
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

2.  Immunosuppressive function of hepatitis B antigens in vitro: role of endoribonuclease V as one potential trans inactivator for cytokines in macrophages and human hepatoma cells.

Authors:  C Jochum; R Voth; S Rossol; K H Meyer zum Büschenfelde; G Hess; H Will; H C Schröder; R Steffen; W E Müller
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein.

Authors:  E Gordien; O Rosmorduc; C Peltekian; F Garreau; C Bréchot; D Kremsdorf
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Liver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.

Authors:  J Petersen; M Dandri; S Gupta; C E Rogler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-06       Impact factor: 11.205

5.  Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides.

Authors:  E Matthes; P Langen; M von Janta-Lipinski; H Will; H C Schröder; H Merz; B E Weiler; W E Müller
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 6.  Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis.

Authors:  M Haria; P Benfield
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

7.  Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.

Authors:  Adel Samson; Matthew J Bentham; Karen Scott; Gerard Nuovo; Abigail Bloy; Elizabeth Appleton; Robert A Adair; Rajiv Dave; Adam Peckham-Cooper; Giles Toogood; Seishi Nagamori; Matthew Coffey; Richard Vile; Kevin Harrington; Peter Selby; Fiona Errington-Mais; Alan Melcher; Stephen Griffin
Journal:  Gut       Date:  2016-11-15       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.